vaccines

BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
Biopharma Reporter
BioNTech
earnings
COVID-19
vaccines
Flag link:
Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
Seeking Alpha
Pfizer
Valneva
clinical trials
vaccines
Lyme disease
VLA15
Flag link:
Moderna CEO defends price of COVID shot at Senate hearing
Moderna CEO defends price of COVID shot at Senate hearing
BioPharma Dive
Moderna Therapeutics
vaccines
COVID-19
drug pricing
Senate
Bernie Sanders
Stephane Bancel
Flag link:
FDA to soon decide on second round of Omicron-tailored boosters
FDA to soon decide on second round of Omicron-tailored boosters
Reuters
COVID-19
vaccines
boosters
Omicron
FDA
Flag link:
The Rise, Fall and Future of Novavax
The Rise, Fall and Future of Novavax
BioSpace
Novavax
vaccines
COVID-19
Flag link:
FDA offers radio silence on question of spring Covid boosters, as other countries push ahead
FDA offers radio silence on question of spring Covid boosters, as other countries push ahead
Stat
FDA
boosters
vaccines
COVID-19
Flag link:
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Shot in Young Children
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Shot in Young Children
Yahoo/Zacks.com
Pfizer
BioNTech
FDA
pediatric
COVID-19
bivalent boosters
vaccines
Flag link:
Hookipa halts spending on cytomegalovirus vaccine after seeing phase 2 data
Hookipa halts spending on cytomegalovirus vaccine after seeing phase 2 data
Fierce Biotech
Hookipa
CMV
vaccines
HB-101
kidney transplants
Flag link:
Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win
Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win
Fierce Pharma
vaccines
GSK
Pfizer
meningococcal disease
Menveo
Bexsero
Flag link:
Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe
Pfizer ready to launch RSV vaccines for older adults, pregnant women in US, Europe
Reuters
Pfizer
GSK
vaccines
RSV
Flag link:
Merck pays $50 million for early-stage Epstein-Barr vaccine
Merck pays $50 million for early-stage Epstein-Barr vaccine
BioPharma Dive
Merck
OPKO Health
vaccines
Epstein-Barr virus
Flag link:
Moderna's COVID vaccine gambit: Hike the price, offer free doses for uninsured
Moderna's COVID vaccine gambit: Hike the price, offer free doses for uninsured
NPR
Moderna Therapeutics
vaccines
COVID-19
drug pricing
Flag link:
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
Yahoo/Zacks.com
GSK
Pfizer
FDA
vaccines
RSV
Flag link:
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine
BioSpace
Moderna Therapeutics
MRNA
vaccines
cancer
cancer vaccines
Flag link:
US spent nearly $32B in public funds on mRNA vaccine development, study finds
US spent nearly $32B in public funds on mRNA vaccine development, study finds
Endpoints
federal government
funding
COVID-19
vaccines
Flag link:
Moderna May Be Just Getting Started in This Big Market
Moderna May Be Just Getting Started in This Big Market
Motley Fool
Moderna Therapeutics
vaccines
Flag link:
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children
PM Live
Pfizer
BioNTech
FDA
COVID-19
boosters
vaccines
pediatric
Flag link:
FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks
FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks
CNBC
GSK
RSV
vaccines
FDA
Flag link:
Pfizer's RSV vaccine wins support of FDA panel despite lingering safety and efficacy questions
Pfizer's RSV vaccine wins support of FDA panel despite lingering safety and efficacy questions
Fierce Biotech
Pfizer
RSV
vaccines
Abrysvo
FDA
Flag link:
Novavax shares plunge as company raises doubts about its ability to remain in business
Novavax shares plunge as company raises doubts about its ability to remain in business
CNBC
Novavax
vaccines
COVID-19
Flag link:

Pages